Summary
Global Markets Direct’s, ‘Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2016’, provides in depth analysis on Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted pipeline therapeutics.
The report provides comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development and features dormant and discontinued projects.
Browse Complete Summary Click Here @ http://www.radiantinsights.com/research/integrin-beta-3-platelet-membrane
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
– The report reviews Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics and enlists all their major and minor projects
– The report assesses Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics
Related Reports by Radiant Insights:
Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) – Pipeline Review, H1 2016 –
http://www.radiantinsights.com/research/potassium-voltage-gated-channel-subfamily-kqt-member-2
DNA Gyrase Subunit B (EC 5.99.1.3) – Pipeline Review, H1 2016 –
http://www.radiantinsights.com/research/dna-gyrase-subunit-b-ec-5-99-1-3-pipeline-review-h1-2016
Reasons To Buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) Overview 7
Therapeutics Development 8
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Products under Development by Stage of Development 8
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Products under Development by Therapy Area 9
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Products under Development by Indication 10
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Products under Development by Companies 14
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Products under Development by Universities/Institutes 16
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Companies Involved in Therapeutics Development 24
Merck & Co., Inc. 24
SciFluor Life Sciences, LLC 25
Tissue Therapies Limited 26
TWi Pharmaceuticals, Inc. 27
Vascular Pharmaceuticals, Inc. 28
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Drug Profiles 29
A-11 – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AC-301 – Drug Profile 30
Buy a Sample copy of This Report @ http://www.radiantinsights.com/research/integrin-beta-3-platelet-membrane/request-sample
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: California
Country: United States
Website: http://www.radiantinsights.com/research/integrin-beta-3-platelet-membrane